GSK961081: Phase IIb started

GlaxoSmithKline began a double-blind, double-dummy, placebo-controlled, international Phase IIb trial in about 425 patients to evaluate once-daily 100, 400 or 800 µg doses or twice-daily 100, 200 or 4...